Dysregulated biomarkers of innate and adaptive immunity predict infections and disease progression in cirrhosis

被引:14
|
作者
Simbrunner, Benedikt [1 ,2 ,3 ,4 ,5 ]
Hartl, Lukas [1 ,2 ]
Jachs, Mathias [1 ,2 ]
Bauer, David J. M. [1 ,2 ]
Scheiner, Bernhard [1 ,2 ]
Hofer, Benedikt Silvester [1 ,2 ,3 ]
Staettermayer, Albert Friedrich [1 ,2 ]
Marculescu, Rodrig [6 ]
Trauner, Michael [1 ]
Mandorfer, Mattias [1 ,2 ]
Reiberger, Thomas [1 ,2 ,3 ,4 ,5 ]
机构
[1] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Med 3, Div Gastroenterol & Hepatol, Vienna Hepat Hemodynam Lab, Vienna, Austria
[3] Med Univ Vienna, Christian Doppler Lab Portal Hypertens & Liver Fib, Vienna, Austria
[4] Ludwig Boltzmann Inst Rare & Undiagnosed Dis LBI R, Vienna, Austria
[5] Austrian Acad Sci, CeMM Res Ctr Mol Med, Vienna, Austria
[6] Med Univ Vienna, Dept Lab Med, Vienna, Austria
关键词
ACLD; Portal hypertension; Gut-liver axis; Immune dysfunction; ASCITIC FLUID; DECOMPENSATED CIRRHOSIS; BACTERIAL TRANSLOCATION; COMPLEMENT-SYSTEM; B-CELLS; LIVER; SERUM; INFLAMMATION; ACTIVATION; IGG;
D O I
10.1016/j.jhepr.2023.100712
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Cirrhosis-associated immune dysfunction (CAID) affects both innate and adaptive immunity. This study investigated the complement system, immunoglobulins, and acute-phase proteins and their prognostic relevance in patients with advanced chronic liver disease (ACLD).Methods: Patients with ACLD (hepatic venous pressure gradient [HVPG] >-6 mmHg) but without acute decompensation/in-fections were characterised by HVPG and by clinical EASL stages: compensated (cACLD; S0-2) vs. decompensated ACLD (dACLD) with previous variceal bleeding (S3), non-bleeding decompensation (S4), or further decompensation (S5). Com-plement factors (C3c, C4, CH50), immunoglobulins (IgA, IgM, IgG, IgG1-4), acute-phase proteins and systemic inflammation biomarkers (white blood cells, C-reactive protein, IL-6, procalcitonin) were measured.Results: A total of 245 patients (median model for end-stage liver disease score: 11 [9-15], median HVPG: 17 [12-21] mmHg) were included with 150 (61%) presenting dACLD. Complement levels and activity significantly decreased in dACLD substages S4 and S5 (p <0.001). Total IgA/IgM/IgG and IgG1-4 subtype levels increased in patients with dACLD (all p <0.05). Complement and immunoglobulin levels correlated negatively and positively, respectively, with systemic inflammation (all p <0.05). High IgG-1 (adjusted hazard ratio per 100 mg/dl: 1.12, 1.04-1.19, p = 0.002) and IL-6 (adjusted hazard ratio: 1.03, 1.00-1.05, p = 0.023) levels predicted the development of infections during follow-up. High IgA (stratified by median; log-rank p <0.001), high IgG1 (log-rank p = 0.043) and low C3c (log-rank p = 0.003) indicated a higher risk of first/further decompensation or liver-related death (composite endpoint). Next to HVPG and IL-6, low C3c (adjusted hazard ratio per mg/dl: 0.99, 0.97-0.99, p = 0.040) remained independently associated with the composite endpoint on multivariate Cox regression analysis.Conclusions: Complement levels and immunoglobulins may serve as surrogates of cirrhosis-associated immune dysfunction and associate with cirrhosis severity and systemic inflammation. Low complement C3c predicted decompensation and liver -related death, whereas high IgG-1 indicated an increased risk for infections.Impact and Implications: Patients with cirrhosis are at increased risk for infections, which worsen their prognosis. We found a significant dysregulation of several essential components of the immune system that was linked to disease severity and indicated a risk for infections and other complications. Simple blood tests identify patients at particularly high risk, who may be candidates for preventive measures.Clinical Trials Registration: This study is registered at ClinicalTrials.gov (NCT03267615).& COPY; 2023 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Innate and Adaptive Immunity in Calcific Aortic Valve Disease
    Mathieu, Patrick
    Bouchareb, Rihab
    Boulanger, Marie-Chloe
    JOURNAL OF IMMUNOLOGY RESEARCH, 2015, 2015
  • [22] Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease
    Mckee, Amy S.
    Atif, Shaikh M.
    Falta, Michael T.
    Fontenot, Andrew P.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (08): : 1835 - 1843
  • [23] Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease
    McKee, Amy S.
    Atif, Shaikh M.
    Falta, Michael T.
    Fontenot, Andrew P.
    JOURNAL OF IMMUNOLOGY, 2022, 208 (09): : 1835 - 1843
  • [24] Innate and adaptive immunity: the Yin and Yang of celiac disease
    Jabri, B
    Kasarda, DD
    Green, PHR
    IMMUNOLOGICAL REVIEWS, 2005, 206 : 219 - 231
  • [25] Behcet's disease: from innate to adaptive immunity
    Direskeneli, H
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 2) : S4 - S4
  • [26] Innate and Adaptive Immunity for the Pathobiology of Parkinson's Disease
    Stone, David K.
    Reynolds, Ashley D.
    Mosley, R. Lee
    Gendelman, Howard E.
    ANTIOXIDANTS & REDOX SIGNALING, 2009, 11 (09) : 2151 - 2166
  • [27] Suppression of HCC Initiation or Progression By Systemic Activation of Innate and Adaptive Immunity
    Wen, Liang
    Xin, Bing
    Wu, Panyisha
    Lee, Jin
    Feng, GenSheng
    HEPATOLOGY, 2018, 68 : 65A - 65A
  • [28] RELATIONSHIP BETWEEN THE INNATE AND ADAPTIVE IMMUNITY IN INFECTIONS (REVISION OF CLASSIC DOGMA)
    Freidlin, I. S.
    INFEKTSIYA I IMMUNITET, 2011, 1 (03): : 199 - 206
  • [29] Blocking innate immunity to slow the progression of chronic kidney disease
    Christoph Schmaderer
    Uwe Heemann
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2014, 387 : 905 - 907
  • [30] Blocking innate immunity to slow the progression of chronic kidney disease
    Schmaderer, Christoph
    Heemann, Uwe
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2014, 387 (10) : 905 - 907